Cargando…

Strong EGFR signaling in cell line models of ERBB2-amplified breast cancer attenuates response towards ERBB2-targeting drugs

Increasing the efficacy of targeted cancer therapies requires the identification of robust biomarkers suitable for patient stratification. This study focused on the identification of molecular mechanisms causing resistance against the anti-ERBB2-directed therapeutic antibodies trastuzumab and pertuz...

Descripción completa

Detalles Bibliográficos
Autores principales:	Henjes, F, Bender, C, von der Heyde, S, Braun, L, Mannsperger, H A, Schmidt, C, Wiemann, S, Hasmann, M, Aulmann, S, Beissbarth, T, Korf, U
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 2012
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3412653/ https://www.ncbi.nlm.nih.gov/pubmed/23552733 http://dx.doi.org/10.1038/oncsis.2012.16

Ejemplares similares

Boolean ErbB network reconstructions and perturbation simulations reveal individual drug response in different breast cancer cell lines
por: der Heyde, Silvia Von, et al.
Publicado: (2014)

Inferring signalling networks from longitudinal data using sampling based approaches in the R-package 'ddepn'
por: Bender, Christian, et al.
Publicado: (2011)

Disentangling ERBB Signaling in Breast Cancer Subtypes—A Model-Based Analysis
por: Kemmer, Svenja, et al.
Publicado: (2022)

Genome profiling of ERBB2-amplified breast cancers
por: Sircoulomb, Fabrice, et al.
Publicado: (2010)

Dynamic deterministic effects propagation networks: learning signalling pathways from longitudinal protein array data
por: Bender, Christian, et al.
Publicado: (2010)

Differential impact of the ERBB receptors EGFR and ERBB2 on the initiation of precursor lesions of pancreatic ductal adenocarcinoma
por: Meyers, Nora, et al.
Publicado: (2020)

Modeling ERBB receptor-regulated G1/S transition to find novel targets for de novo trastuzumab resistance
por: Sahin, Özgür, et al.
Publicado: (2009)

The immune microenvironment in EGFR- and ERBB2-mutated lung adenocarcinoma
por: Kirchner, M., et al.
Publicado: (2021)

Global microRNA level regulation of EGFR-driven cell-cycle protein network in breast cancer
por: Uhlmann, Stefan, et al.
Publicado: (2012)

A reason why the ERBB2 gene is amplified and not mutated in breast cancer
por: Birnbaum, Daniel, et al.
Publicado: (2009)

Modulation of ErbB2 Blockade in ErbB2-Positive Cancers: The Role of ErbB2 Mutations and PHLDA1
por: Li, Guangyuan, et al.
Publicado: (2014)

PTPRO represses ERBB2-driven breast oncogenesis by dephosphorylation and endosomal internalization of ERBB2
por: Dong, H, et al.
Publicado: (2017)

ERRF sensitizes ERBB2-positive breast cancer cells to lapatinib treatment likely by attenuating MCL1 and ERBB2 expression
por: Qi, Leilei, et al.
Publicado: (2017)

Mitochondrial DNA copy number instability in ERBB2-amplified breast cancer tumors
por: Ebrahimi, Elmira, et al.
Publicado: (2018)

SUN-442 EGFR/ErbB2 Targeted Therapy for Aggressive Prolactinomas
por: Cooper, Odelia, et al.
Publicado: (2019)

A monoclonal antibody targeting ErbB2 domain III inhibits ErbB2 signaling and suppresses the growth of ErbB2-overexpressing breast tumors
por: Meng, Y, et al.
Publicado: (2016)

ERBB1- and ERBB2-Positive Medullary Thyroid Carcinoma: A Case Report
por: Minuto, Michele, et al.
Publicado: (2018)

Trastuzumab and pertuzumab in circulating tumor DNA ERBB2-amplified HER2-positive refractory cholangiocarcinoma
por: Yarlagadda, Bhavya, et al.
Publicado: (2019)

Valproic acid exhibits anti-tumor activity selectively against EGFR/ErbB2/ErbB3-coexpressing pancreatic cancer via induction of ErbB family members-targeting microRNAs
por: Lin, Tingting, et al.
Publicado: (2019)

Nucleolin and ErbB2 inhibition reduces tumorigenicity of ErbB2-positive breast cancer
por: Wolfson, Eya, et al.
Publicado: (2018)

Nucleolin-binding by ErbB2 enhances tumorigenicity of ErbB2-positive breast cancer
por: Wolfson, Eya, et al.
Publicado: (2016)

Quantitative Phosphoproteomics Analysis of ERBB3/ERBB4 Signaling
por: Wandinger, Sebastian K., et al.
Publicado: (2016)

Pertuzumab Increases 17-AAG-Induced Degradation of ErbB2, and This Effect Is Further Increased by Combining Pertuzumab with Trastuzumab
por: Hughes, Juliana Bentes, et al.
Publicado: (2012)

Trastuzumab therapy vs tetracycline controlled ERBB2 downregulation: influence on tumour development in an ERBB2-dependent mouse tumour model
por: Hermes, M, et al.
Publicado: (2008)

Increasing the sensitivity of reverse phase protein arrays by antibody-mediated signal amplification
por: Brase, Jan C, et al.
Publicado: (2010)

Mutational Screening in Tyrosine-Kinase Domain of erbB1 And erbB2 Genes
por: ALONSO, Juan Manuel Fernández
Publicado: (2005)

miR-296-5p suppresses EMT of hepatocellular carcinoma via attenuating NRG1/ERBB2/ERBB3 signaling
por: Shi, Dong-Min, et al.
Publicado: (2018)

Blocking c-MET/ERBB1 Axis Prevents Brain Metastasis in ERBB2+ Breast Cancer
por: Gautam, Shailendra K., et al.
Publicado: (2020)

ERBB3 (HER3) is a key sensor in the regulation of ERBB-mediated signaling in both low and high ERBB2 (HER2) expressing cancer cells
por: Choi, Byung-Kwon, et al.
Publicado: (2012)

Targeting HER2 in colorectal cancer: The landscape of amplification and short variant mutations in ERBB2 and ERBB3
por: Ross, Jeffrey S., et al.
Publicado: (2018)

Combining RANK/RANKL and ERBB-2 targeting as a novel strategy in ERBB-2-positive breast carcinomas
por: Zoi, Ilianna, et al.
Publicado: (2019)

Comparison of Management and Outcomes in ERBB2-Low vs ERBB2-Zero Metastatic Breast Cancer in France
por: de Calbiac, Ombline, et al.
Publicado: (2022)

Vaccine-induced ErbB (EGFR/HER2)-specific immunity in spontaneous canine cancer
por: Doyle, Hester A., et al.
Publicado: (2021)

Src Mutation Induces Acquired Lapatinib Resistance in ERBB2-Amplified Human Gastroesophageal Adenocarcinoma Models
por: Hong, Yong Sang, et al.
Publicado: (2014)

Genes co-amplified with ERBB2 or MET as novel potential cancer-promoting genes in gastric cancer
por: Kwon, Mi Jeong, et al.
Publicado: (2017)

Computational design of fusion proteins against ErbB2-amplified tumors inspired by ricin toxin
por: Ahmadi Moghaddam, Yasser, et al.
Publicado: (2023)

Expression of oncogenes in thyroid tumours: coexpression of c-erbB2/neu and c-erbB.
por: Aasland, R., et al.
Publicado: (1988)

ErbB2 Is Necessary for Induction of Carcinoma Cell Invasion by Erbb Family Receptor Tyrosine Kinases
por: Spencer, Kathryn S.R., et al.
Publicado: (2000)

erbB-2 antisense oligonucleotides inhibit the proliferation of breast carcinoma cells with erbB-2 oncogene amplification.
por: Colomer, R., et al.
Publicado: (1994)

The chromodomain helicase CHD4 regulates ERBB2 signaling pathway and autophagy in ERBB2(+) breast cancer cells
por: D'Alesio, Carolina, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_amo1jo0kdii3oc303t03au12sr